--- title: "Blood Tests for Alzheimer's Are Real Now — But Here's What They Can and Can't Do" slug: alzheimers-blood-biomarker-tests-2026 category: health category_label: "Health" author: "BrainWavePost Staff" date: 2026-10-19 tags: ["Alzheimer's", "blood test", "biomarkers", "p-tau217", "amyloid", "early detection", "dementia", "FDA"] read_time_minutes: 9 canonical_url: https://brainwavepost.com/article/alzheimers-blood-biomarker-tests-2026 source: BrainWavePost --- # Blood Tests for Alzheimer's Are Real Now — But Here's What They Can and Can't Do *Health · 2026-10-19 · BrainWavePost Staff · 9 min read* > Blood-based biomarker tests for Alzheimer's are a genuine breakthrough — the FDA cleared the first one in May 2025. But the cleared test is an aid to diagnosis in people who already have cognitive symptoms, not a screen for healthy people 'long before' symptoms, and detecting Alzheimer's pathology isn't the same as predicting who will develop dementia. > **The good news is real — and narrower than the headlines** _(note)_ > > This is a genuine advance: in May 2025 the FDA cleared the first blood test to help diagnose Alzheimer's, and plasma p-tau217 tests are strikingly accurate. But the cleared use is as an aid to diagnosis in adults who already have cognitive symptoms — not a screen for symptom-free people 'long before' onset. The test flags Alzheimer's-type pathology (amyloid/tau), it isn't a standalone diagnosis, and having that pathology doesn't guarantee someone will develop dementia. [1][2][3] For decades, confirming Alzheimer's disease biology required either a PET scan (expensive, with radiation) or a spinal tap (invasive). So a simple blood test that detects the same underlying pathology is a big deal — and that capability now genuinely exists. The key is understanding exactly what it is approved to do, because 'early detection long before symptoms' describes a hope and a research direction more than the tool that's actually in clinics today. [1][3] ## What actually happened: the first FDA clearance On May 16, 2025, the U.S. FDA cleared the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test (from Fujirebio) — the first blood test authorized to aid in diagnosing Alzheimer's disease. It measures two proteins in the blood (phosphorylated tau 217 and beta-amyloid 1-42) and reports their ratio, which correlates with the amyloid buildup seen on PET scans and in spinal fluid. [1][2][3] - **May 2025** — FDA cleared the first blood test to aid Alzheimer's diagnosis (Fujirebio Lumipulse) [1][2] - **Symptomatic** — intended use: adults (~50-55+) already showing cognitive symptoms [2][3] - **92% / 97%** — reported positive / negative predictive value in the validation cohort [2] - **~20%** — of results fell in an intermediate zone needing further testing [2] > **What 'aid to diagnosis' means** _(info)_ > > The test is a decision aid, not a verdict. A result is interpreted alongside a clinical evaluation, and the cleared population is people presenting with signs and symptoms of cognitive decline. Roughly one in five results in validation was intermediate — neither clearly positive nor negative — and needed additional workup. [2] ## The accuracy is genuinely impressive — with caveats Research on plasma p-tau217 has been remarkable. In published studies it detected amyloid pathology about as well as FDA-approved spinal-fluid tests, with accuracy (AUC) around 0.95-0.97 against amyloid PET. In a large primary- and secondary-care study, accuracy ran roughly 85% in primary care and 89-91% in specialist care. But the numbers are lower in two important groups: people aged 80 and older, and — crucially for the 'before symptoms' question — cognitively unimpaired people, where a standalone blood test was less accurate (around 81%) and needed PET confirmation to reach the low 90s. [3][4] ## Where 'long before symptoms' overshoots > **Three things to keep accurate** _(note)_ > > (1) The cleared test is for symptomatic patients, not a general screen for healthy people. (2) Using blood biomarkers to detect preclinical (presymptomatic) Alzheimer's is an active research frontier, not established clinical practice, and accuracy is lower in people without symptoms. (3) Detecting Alzheimer's pathology is not the same as diagnosing dementia or predicting that someone will develop it — amyloid can be present years before symptoms, and not everyone with it progresses to dementia. [1][3][4] It is true that the underlying biology of Alzheimer's — amyloid plaques and tau — begins accumulating years before memory problems become obvious, and blood biomarkers can pick up that biology. That is why the field is so excited. But detecting pathology early raises hard questions the science hasn't fully answered: who should be tested, what an abnormal result means for someone with no symptoms, and what can be done about it. Those are reasons the cleared use is deliberately limited to people who already have symptoms. [3][4] ## Why it still matters a lot - It can confirm or rule out Alzheimer's pathology with a blood draw instead of a PET scan or spinal tap — cheaper, faster, less invasive. [1][2] - In symptomatic patients, it can speed an accurate diagnosis and help avoid misdiagnosis. [1][3] - Accurate biomarker confirmation matters more now that amyloid-targeting treatments exist for early Alzheimer's, since those therapies require confirmed amyloid pathology. [3] - It lays groundwork for the future — but presymptomatic screening needs more evidence before it's ready for routine use. [3][4] ## What the evidence supports - Real breakthrough: the first FDA-cleared Alzheimer's blood test (Fujirebio Lumipulse) arrived in May 2025. [1][2] - Cleared use: an aid to diagnosis in adults already showing cognitive symptoms — not asymptomatic screening. [2][3] - Plasma p-tau217 is highly accurate against PET/CSF in symptomatic people (AUC ~0.95-0.97), but less so in the very old and in cognitively unimpaired people. [3][4] - It detects Alzheimer's-type pathology; it is not a standalone diagnosis, and ~20% of results need further testing. [2] - Presymptomatic detection is promising but a research frontier, and pathology does not equal destined dementia. [3][4] > **Editorial note** _(tip)_ > > This is educational health journalism, not medical advice. Decisions about Alzheimer's testing, diagnosis and treatment belong with qualified clinicians, who weigh a blood biomarker result alongside a full clinical evaluation. ## Sources and further reading - [1] U.S. FDA — 'FDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease' (May 16, 2025): https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease - [2] Fujirebio — 'Marketing Clearance for Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio' (intended use and validation): https://www.fujirebio.com/en-us/news-events/fujirebio-receives-marketing-clearance-for-lumipulser-g-ptau-217bamyloid-142-plasma-0 - [3] Nature Medicine (2025) — 'Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform': https://www.nature.com/articles/s41591-025-03622-w - [4] Nature Medicine (2024) — 'Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests': https://www.nature.com/articles/s41591-024-02869-z - [5] NeurologyLive — 'FDA Clears Lumipulse Plasma Ratio as First Blood Test for Diagnosing Alzheimer Disease': https://www.neurologylive.com/view/fda-clears-lumipulse-plasma-ratio-first-blood-test-diagnosing-alzheimer-disease --- _Canonical article: [https://brainwavepost.com/article/alzheimers-blood-biomarker-tests-2026](https://brainwavepost.com/article/alzheimers-blood-biomarker-tests-2026) — © BrainWavePost. Educational content; see the article page for full disclaimers._